HanchorBio Inc. (TPE:7827)
Taiwan · Delayed Price · Currency is TWD 159.50
-2.50 (-1.54%)
At close: Aug 28, 2026
HanchorBio Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| 321.77 | 312.22 | - | - | 3.36 | |
Revenue Growth | - | - | - | - | - |
Cost of Revenue | 8.92 | - | - | - | 1.32 |
Gross Profit | 312.84 | 312.22 | - | - | 2.05 |
Selling, General & Admin | 175.35 | 131.74 | 162.88 | 38.84 | 52.95 |
Research & Development | 862.11 | 548.08 | 789.24 | 499.21 | 461.42 |
Operating Expenses | 1,037 | 679.82 | 952.12 | 538.05 | 514.37 |
Operating Income | -724.62 | -367.6 | -952.12 | -538.05 | -512.32 |
Interest Expense | -3.24 | -2.93 | -4.9 | -2.77 | -2.5 |
Interest & Investment Income | 20.63 | 12.91 | 6.28 | 7.91 | 1.29 |
Currency Exchange Gain (Loss) | -8.43 | -8.43 | -5.36 | 3.12 | -15.62 |
Other Non Operating Income (Expenses) | -6.77 | -2.89 | -399.12 | -65.44 | 81.72 |
EBT Excluding Unusual Items | -722.43 | -368.94 | -1,355 | -595.23 | -447.43 |
Gain (Loss) on Sale of Investments | - | - | 1.12 | 0.94 | 1.13 |
Other Unusual Items | - | - | - | 2.92 | - |
Pretax Income | -722.43 | -368.94 | -1,354 | -591.37 | -446.3 |
Income Tax Expense | 32.07 | 22.58 | - | - | - |
Earnings From Continuing Operations | -754.49 | -391.52 | -1,354 | -591.37 | -446.3 |
Minority Interest in Earnings | 181.91 | 114.79 | - | 0.02 | -0.02 |
Net Income | -572.58 | -276.72 | -1,354 | -591.36 | -446.32 |
Net Income to Common | -572.58 | -276.72 | -1,354 | -591.36 | -446.32 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 129 | 123 | 67 | 52 | 44 |
Shares Outstanding (Diluted) | 129 | 123 | 67 | 52 | 44 |
Shares Change | 32.00% | 84.41% | 27.71% | 17.68% | - |
EPS (Basic) | -4.45 | -2.26 | -20.36 | -11.36 | -10.09 |
EPS (Diluted) | -4.45 | -2.26 | -20.36 | -11.36 | -10.09 |
EPS Growth | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Free Cash Flow | -538.44 | -335.58 | -626.45 | -461.63 | -408.39 |
Free Cash Flow Per Share | -4.18 | -2.74 | -9.42 | -8.87 | -9.23 |
Gross Margin | 97.23% | 100.00% | - | - | 60.87% |
Operating Margin | -225.20% | -117.74% | - | - | -15234.11% |
Profit Margin | -177.95% | -88.63% | - | - | -13271.57% |
Free Cash Flow Margin | -167.34% | -107.48% | - | - | -12143.74% |
EBITDA | -698.66 | -342.91 | -927.86 | -515.61 | -495.85 |
EBITDA Margin | -217.13% | -109.83% | - | - | - |
D&A For EBITDA | 25.96 | 24.69 | 24.26 | 22.45 | 16.48 |
EBIT | -724.62 | -367.6 | -952.12 | -538.05 | -512.32 |
EBIT Margin | -225.20% | -117.74% | - | - | - |